Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables - Other (2016 - 2024)

Historic Receivables - Other for Ascendis Pharma A (ASND) over the last 9 years, with Q4 2024 value amounting to $10.0 million.

  • Ascendis Pharma A's Receivables - Other fell 5119.16% to $10.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $10.0 million, marking a year-over-year decrease of 5119.16%. This contributed to the annual value of $10.2 million for FY2024, which is 5056.39% down from last year.
  • Ascendis Pharma A's Receivables - Other amounted to $10.0 million in Q4 2024, which was down 5119.16% from $20.5 million recorded in Q4 2023.
  • Ascendis Pharma A's Receivables - Other's 5-year high stood at $23.0 million during Q4 2021, with a 5-year trough of $219381.3 in Q4 2020.
  • For the 5-year period, Ascendis Pharma A's Receivables - Other averaged around $13.4 million, with its median value being $13.1 million (2022).
  • In the last 5 years, Ascendis Pharma A's Receivables - Other plummeted by 9673.59% in 2020 and then surged by 1037756.08% in 2021.
  • Ascendis Pharma A's Receivables - Other (Quarter) stood at $219381.3 in 2020, then surged by 10377.56% to $23.0 million in 2021, then crashed by 43.04% to $13.1 million in 2022, then skyrocketed by 56.93% to $20.5 million in 2023, then tumbled by 51.19% to $10.0 million in 2024.
  • Its Receivables - Other was $10.0 million in Q4 2024, compared to $20.5 million in Q4 2023 and $13.1 million in Q4 2022.